belantamab mafodotin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antitumor, monoclonal antibodies 5405 2050232-20-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • belantamab mafodotin
  • belantamab
  • belantamab mafodotin-blmf
  • blenrep
  • anti-BCMA-ADC
  • GSK2857914
  • GSK-2857916
  • J6M0-mcMMAF
Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 25, 2020 EMA GlaxoSmithKline (Ireland) Limited
May 8, 2020 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 974.54 71.37 116 901 447 56290603
Visual acuity reduced 527.42 71.37 111 906 20615 56270435
Night blindness 435 71.37 55 962 368 56290682
Dry eye 218.96 71.37 61 956 35655 56255395
Plasma cell myeloma 181.37 71.37 56 961 46590 56244460
Foreign body sensation in eyes 153.04 71.37 27 990 1900 56289150
Death 115.81 71.37 73 944 341353 55949697
Photophobia 100.64 71.37 28 989 16022 56275028

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1279.99 62.02 158 1113 311 31695762
Visual acuity reduced 645.06 62.02 143 1128 15200 31680873
Night blindness 468.02 62.02 60 1211 171 31695902
Dry eye 265.67 62.02 62 1209 8010 31688063
Foreign body sensation in eyes 171.19 62.02 28 1243 547 31695526
Photophobia 152.57 62.02 38 1233 6391 31689682
Plasma cell myeloma 143.49 62.02 61 1210 56470 31639603
Punctate keratitis 117.05 62.02 19 1252 352 31695721
Corneal epithelial microcysts 115.98 62.02 13 1258 3 31696070
Death 89.46 62.02 89 1182 360480 31335593
Corneal disorder 70.45 62.02 14 1257 831 31695242
Keratitis 69.95 62.02 15 1256 1296 31694777

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1703.02 57.95 212 1746 758 70925728
Visual acuity reduced 911.63 57.95 198 1760 27732 70898754
Night blindness 696.81 57.95 89 1869 394 70926092
Dry eye 394.66 57.95 104 1854 32178 70894308
Foreign body sensation in eyes 281.45 57.95 48 1910 1794 70924692
Plasma cell myeloma 210.47 57.95 78 1880 73123 70853363
Photophobia 189.19 57.95 52 1906 18598 70907888
Corneal epithelial microcysts 161.25 57.95 18 1940 13 70926473
Punctate keratitis 133.76 57.95 23 1935 897 70925589
Ocular toxicity 101.87 57.95 18 1940 823 70925663
Death 88.77 57.95 88 1870 509973 70416513
Keratitis 80.20 57.95 19 1939 3738 70922748
Corneal disorder 73.46 57.95 16 1942 2163 70924323
Corneal epithelium defect 65.30 57.95 12 1946 684 70925802

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX15 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
IgG receptor FcRn large subunit p51 Membrane receptor BINDING AGENT Kd 7.28 DRUG LABEL DRUG LABEL
High affinity immunoglobulin gamma Fc receptor I Membrane receptor BINDING AGENT Kd 8.15 DRUG LABEL DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A Membrane receptor BINDING AGENT Kd 7.55 DRUG LABEL DRUG LABEL
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen BINDING AGENT Kd 9 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D11595 KEGG_DRUG
DB1041CXDG UNII
2061894-48-0 SECONDARY_CAS_RN
C5227411 UMLSCUI
CHEMBL4298209 ChEMBL_ID
DB15719 DRUGBANK_ID
CHEMBL4298208 ChEMBL_ID
11117 IUPHAR_LIGAND_ID
337068 MMSL
38715 MMSL
d09613 MMSL
4039621 VANDF
4039622 VANDF
10797 INN_ID
018466 NDDF
895362005 SNOMEDCT_US
896748005 SNOMEDCT_US
C000631691 MESH_SUPPLEMENTAL_RECORD_UI
10754 INN_ID
2387833 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections